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Background: HOX-7 is a newly developed dietary formula composed of traditional oriental herbal medicines. The
formula was developed with the aim of improving weight control. We investigated the anti-obesity effect of HOX-7
on high-fat-diet (HFD)-induced obesity in C57BL/6 mice.
Methods: The mice were divided into four groups and were fed a normal diet (ND), HFD, or HFD with oral administration
of HOX-7 at 100 or 200 mg/kg/day for 12 weeks. Body and fat weight, histological changes of fat tissue, and the
expression of key adipogenic transcription factors were investigated.
Results: The body weight of mice fed the HFD with HOX-7 was significantly decreased compared to the HFD
group. There were no obvious differences in weekly food intake among the 4 groups. The weight of the epididymal
and total fat pads was reduced in mice fed the HFD with HOX-7. Treatment with HOX-7 also substantially attenuated
the expression of key adipogenic transcription factors, including peroxisome proliferatoractivated receptor γ,
CCAAT/enhancer binding protein α, sterol regulatory element binding protein 1c, adipocyte P2, liver X receptor, and
lipoprotein lipase in the epididymal adipose tissue.
Conclusion: Overall, this study highlighted the anti-obesity effects of HOX-7, a finding that could contribute to the
development of natural anti-obesity herbal medicines.
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Obesity is one of the most prevalent metabolic diseases
in the world and constitutes a serious threat in both in-
dustrialized and developing countries [1]. It is connected
with the genesis or development of various diseases, such
as hypertension, cardiac arrhythmia, constipation, head-
ache, steatorrhea, type 2 diabetes mellitus, and cancer [2,3].
The process of gaining fat involves increased adipogenesis
accompanied by adipocyte differentiation. This differenti-
ation is regulated by a highly organized cascade involving
numerous transcription factors [4]. Among them, peroxi-
some proliferator-activated receptor γ (PPARγ), CCAAT/
enhancer binding protein α (C/EBPα), and sterol regulatory* Correspondence: hjan@sj.ac.kr
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unless otherwise stated.element binding protein 1c (SREBP1c) are the major tran-
scriptional genes involved in adipogenesis [4,5].
To target obesity, current pharmacotherapy strategies
are grouped into two categories [6]. The first category is
to medicate people with obesity with drugs, including sup-
pressants and anorexics, that can suppress food intake by
regulating the central nervous system. The second cat-
egory involves drugs that inhibit the absorption of specific
nutrients in food [7]. However, these drugs, of which there
are two varieties, can have undesirable side effects, such as
hypertension, cardiac arrhythmia, constipation, and head-
ache [8].
Because of the unavoidable side effects of the currently
available anti-obesity drugs, the development of herbal
medicinal products to treat obesity has become a global
focus and there are many studies concerning natural med-
icines that might have beneficial effects in obese patients.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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berberine, prunetin, aster glehni, and taeumjowi-tang have
proven anti-obesity effects [9-12]. As well as these studies,
there is a lot of research in progress globally to develop ef-
fective and safe natural anti-obesity drugs.
HOX-7 is a newly combined formula for treating obesity,
composed of seven herbs (Coicis semen, Nelumbo nucifera,
Saliconia herbacea, Polygoni Multiflori Radix, Raphani
semen, Piperis Longi Fructus, and Atractylodis Rhizoma).
Coicis semen is an adlay seed and was reported to have
anti-obesity effects in humans [13]. Nelumbo nucifera has
also been reported to show anti-obesity and hypolipidemic
effects and decrese the expression of PPARγ [14]. Recent
research on Saliconia herbacea revealed its antioxidant
and anti-proliferative properties [15]. In addition, Salico-
nia herbacea has also been reported to have an adipogene-
sis inhibition effect [16]. Polygoni Multiflori Radix has
been used in the treatment of obesity and hyperlipidemia
in East Asian countries for centuries, and a recent study
demonstrated its effects in obesity [17]. Raphani Semen,
commonly known as radish seed, is used as a trad-
itional medicine to treat constipation, chronic tracheitis,
and hypertension [18]. Furthermore, Raphani Semen, which
has a high linolenic acid content, could have effects that re-
duce the risk of cardiovascular disease and was revealed
to have anti-oxidative activity [19]. Piperis Longi Fructus
was verified for its anti-diabetic and anti-hyperlipidemic
effects [20]. Atractylodis Rhizoma was discovered to have
an anti-inflammatory effect [21] and anti-obesity effect in
3T3-L1 cells and animal model [22]. Based on these stud-
ies, we examined the anti-obesity effects of HOX-7 in
high-fat-diet (HFD)-induced obese mice.
Methods
Reagents
Coicis semen, Nelumbo nucifera, Saliconia herbacea, Poly-
goni Multiflori Radix, Raphani Semen, Piperis Longi Fructus,
and Atractylodis Rhizoma were purchased from Omniherb
Co. Ltd (Daegu, Republic of Korea). The normal diet
(ND) and HFD were obtained from Research Diets (New
Brunswick, NJ, USA). PPARγ, C/EBPα, SREBP1c, and
β-actin monoclonal antibodies were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). The other
reagents were purchased from Sigma-Aldrich (St. Louis,
MO, USA).
Preparation of HOX-7 extract
HOX-7 is composed of Coicis semen (260 g), Nelumbo
nucifera (416 g), Saliconia herbacea (91 g), Polygoni
Multiflori Radix (130 g), Raphani Semen (143 g), Piperis
Longi Fructus (52 g), and Atractylodis Rhizoma (208 g).
The dried herbs were refluxed with 70% ethanol for 3 h
at 80°C. The extract was filtered and refluxed again
under the same conditions. After filtration, the extractwas completely dried using a freeze-dryer to obtain a
solid ethanol extract. The yield was 17% (17 g per 100 g
of total materials)
Animal experiments
Male C57BL/6 J mice (3 – 4 weeks) were purchased
from Daehan Biolink (DaeJeon, Republic of Korea). Mice
were maintained (4 mice/cage) under a 12 h light/dark
cycle, at 22 ± 2°C, and a relative humidity of 55 ± 10%,
under conditions that followed the National Institutes of
Health guidelines and were approved by the Ethical
Committee for Animal Care and the Use of Laboratory
Animals, Sangji University (reg. no. 2014–3). Mice were
given the diet and water ad libitum. After 1 week of accli-
mation, 32 mice were divided randomly and equally into 4
groups (n = 8 per group); the ND group, HFD group, and
HFD with HOX-7 at 100 or 200 mg/kg (H100 or H200 re-
spectively). ND group were fed a commercial standard
chow diet and HFD group were fed the HFD for 12 weeks.
HOX-7 was dissolved in DW and, orally and daily ad-
ministrated for 12 weeks with HFD. Food intake and body
weight were recorded every week. At the end of the ex-
perimental period, the mice were fasted overnight. The
next day, animals were anesthetized with zoletil (Virbac,
Carros Cedex, France) and their visceral fat pads were ex-
cised, weighed immediately, and stored at −80°C.
Histological analysis
Representative epididymal adipose tissues from each
group were fixed with 4% paraform aldehyde and em-
bedded in paraffin. Sections of adipose tissue were cut
and stained with hematoxylin and eosin (H&E) for ana-
lysis of adipocyte surface area and diameter. The images
of the stained slides were observed using a SZX10 micro-
scope (Olympus, Seoul, Republic of Korea) and photo-
graphed. Digital images were taken from each slide (5 per
group), and adipocyte diameters were measured using
Image J software.
Quantitative Real-time polymerase chain reaction (PCR)
analysis
Total RNA was isolated from the homogenized epididymal
adipose tissues using TRIzol Reagent (Life Technologies,
NY, USA), according to the manufacturer’s instructions.
The total RNA was then quantified using an Epoch micro-
volume spectrophotometer system (BioTek Instruments
Inc, VT, USA). Synthesis of cDNA was carried out with
quantified equal amounts of total RNA using a high-capacity
cDNA reverse transcription kit (Applied Biosystems, CA,
USA). The program was set for 60 min of initiation at 45°C,
followed by 5 min of incubation at 95°C, and then main-
tained at 4°C. A Step One Plus® Real-time PCR system
with an SYBR Green Master Mix (Applied Biosystems)
and primers (Bioneer, Seoul, Republic of Korea) were used
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shown in Table 1. The steps were as follows: 10 min at
95°C, 40 cycles of 15 s at 95°C, 45 s at 58°C, a final melt-
ing curve of 15 s at 95°C, 1 min at 60°C, and 15 s at
95°C. Fold changes of gene expression were calculated
using the comparative threshold cycle (Ct) method
(Applied Biosystems). Each value was normalized for the
initial control, glyceraldehydes-3-phosphate dehydrogen-
ase (GAPDH).Western blot analysis
The epididymal tissues dissected from the experimental
animals were homogenized in a commercial lysis buffer
PRO-PREP® (Intron Biotechnology Inc., Gyeongi-do,
Republic of Korea) and centrifuged at 13000 rpm (4°C)
for 5 min. Subsequently, the supernatant was transferred
to a fresh 1.5 ml tube. The quantification of the pro-
tein was carried out using Bio-Rad protein assay reagent.
Each protein sample was loaded on Tris-glycine SDS-
polyacrylamide gels, followed by transfer to polyvinylidene
difluoride (PVDF) membranes (Millipore, MA, USA). The
membranes were then blocked with 5% skim milk in Tris-
buffered saline containing 0.1% Tween 20 (TBST) at room
temperature for 1 h and incubated at 4°C overnight with
1:1000 dilutions of the primary antibodies. The following
day, the membranes were washed with TTBS 3 times for
10 min each and reacted with 1:2500 dilutions of the sec-
ondary antibodies for 2 h at room temperature. After reac-
tion, immunoreactive protein bands were visualized using
enhanced chemiluminescence (Santa Cruz Biotechnology).
Bio-rad Quantity One® Software was used for the densito-
metric analysis.Statistical analysis
All the values reported have been expressed as the mean ±
SE. Data were analyzed using one-way analysis of variance
(ANOVA) with Dunnett’s test. Statistical analysis was per-
formed using GraphPad Prism (version 5) and P < 0.05 was













Effects of HOX-7 on body weight and total fat mass in
HFD-induced obese mice
Figure 1 indicates the changes in body weight and the
visceral fat pads, both of which were obviously greater in
the HFD group than in the ND group. However, the
weights in the H100 and H200 groups were less than
those in the HFD group (Figure 1A). Moreover, although
there was no significant difference in food intake, the
weight gain showed certain differences between the HFD
group and HOX-7 groups (Figure 1B and C). Changes in
the weight of the visceral fat pads, including the epididy-
mal, retroperitoneal, and mesenteric fat pads, were in line
with body weight changes (Figure 1D). The HFD group
fats were more highly induced than any other group,
whereas the HOX-7 groups showed evident suppression
of fat production.
Effect of HOX-7 on the accumulation of lipid droplets in
epididymal adipose tissue
To determine whether the observed decrease in body
and visceral fat weight was due to reduced accumulation
of fat, we stained representative adipose tissues with
H&E. As shown in Figure 2, enlargement of adipocytes in
the visceral adipose tissue of mice in the HFD group was
clearer than that the ND group. In addition, it was revealed
that lipid accumulation in the visceral adipose tissue was
definitely suppressed in the H100 and H200 groups com-
pared with the HFD group (Figure 2A). Because fatty
degeneration in adipose tissues is easy to identify, we
compared the diameter of lipid droplets in the adipose tis-
sues. As shown in Figure 2B, administration of HOX-7
significantly decreased the diameter of the lipid droplets.
Effects of HOX-7 on the expression of adipocyte-specific
mRNAs
To determine the inhibitory effects of HOX-7 on adipo-
genic mRNA expression induced by the HFD in epididymal
adipose tissue, we carried out a quantitative real-time PCR
analysis. HOX-7 decreased the expression of mRNA with
regard to adipogenesis. PPARγ, the adipogenic key tran-
scription factor, was significantly reduced in the adipose tis-
sue taken from the HOX-7-treated HFD groups in a
concentration dependent manner (Figure 3A). In addition,
C/EBPα and SREBP1c showed similarly reduced expression
(Figure 3B and C). Other adipogenic markers such as adi-
pocyte P2 (aP2), lipoprotein lipase (LPL), and liver X recep-
tor (LXR) were markedly reduced in the epididymal
adipose tissue of HOX-7-treated mice (Figure 3D - F).
Effects of HOX-7 on the expression of adipocyte-specific
proteins
To confirm the inhibitory effects of HOX-7 on adipogenic
mRNA expression, the expression of key adipogenic
Figure 1 Effects of HOX-7 on body weight gain, fat-pads weights in HFD mice. Mice were fed ND or HFD for 12 weeks in the presence or
absence of HOX-7. (A) Total body (g). (B) Body weight gain (g). (C) Food intake. (D) Visceral fat-pad weight. ND: Normal diet group; HFD: High fat
diet group; H100: HOX-7 (100 mg/kg/day, po) treated with HFD group; H200: HOX-7 (200 mg/kg/day, po) treated with HFD group. The values are
represented as mean ± SE (n = 8). #P < 0.05 versus ND group. *P < 0.05, **P < 0.01, and ***P < 0.001 versus HFD group.
Figure 2 Effect of HOX-7 on accumulation of lipid droplets in epididymal adipose tissue. (A) Representative histological images of the
epididymal adipose tissue were assessed by H&E staining and examined using a light microscope; magnification: ×400. (B) Adipocyte diameter.
ND: Normal diet group; HFD: High fat diet group; H100: HOX-7 (100 mg/kg/day, po) treated with HFD group; H200: HOX-7 (200 mg/kg/day, po)
treated with HFD group. #P < 0.05 versus ND group. **P < 0.01, and ***P < 0.001 versus HFD group.
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Figure 3 Effects of HOX-7 on mRNA expression of adipogenesis related genes in epididymal adipose tissue. mRNA expression of (A) PPARγ,
(B) C/EBPα, (C) SREBP1c, (D) aP2, (E) LPL, (F) LXR. Total RNA was prepared for the real-time-PCR analysis of adipogenesis-related genes expressions
from adipose tissues. Real-time PCR analysis was conducted using a Step One Plus® Real-time PCR system. Data were normalized to the
GAPDH mRNA levels. ND: Normal diet group; HFD: High fat diet group; H100: HOX-7 (100 mg/kg/day, po) treated with HFD group; H200:
HOX-7 (200 mg/kg/day, po) treated with HFD group. The values are represented as mean ± SE (n = 8) of three independent experiments.
#P < 0.05 versus ND group. *P < 0.05, **P < 0.01, and ***P < 0.001 versus HFD group.
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parallel with mRNA expression, the amounts of the
PPARγ, C/EBPα, and SREBP1c proteins were reduced
in epididymal adipose tissue obtained from HOX-7-
treated HFD mice than from mice given HFD alone
(Figure 4).Figure 4 Effects of HOX-7 on expression of adipogenesis related prot
by Western blotting. ND: Normal diet group; HFD: High fat diet group; H10
(200 mg/kg/day, po) treated with HFD group. The values are represented a
group. **P < 0.01, and ***P < 0.001 versus HFD group.Discussion
Globally, obesity is the most prevalent health problem
affecting all age groups and numerous studies have fo-
cused on developing natural anti-obesity herbal medicines
[23]. In line with these worldwide trends in anti-obesity
research, we investigated the anti-obesity effect of HOX-7eins. Protein levels of PPARγ, C/EBPα, and SREBP1c were determined
0: HOX-7 (100 mg/kg/day, po) treated with HFD group; H200: HOX-7
s mean ± SE of three independent experiments. #P < 0.05 versus ND
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ceral fat weight in HFD-induced obese mouse model.
In addition, we found that HOX-7 suppressed adipogene-
sis in epididymal adipose tissues.
Obesity is the result of a complicated process regulated
by a number of adipogenic transcription factors [24].
PPARγ is a ligand-activated transcriptional factor that has
a key role in adipocyte differentiation [25]. It is mostly
expressed in adipose tissues and required for differenti-
ation of preadipocytes to mature adipocytes [25]. PPARγ
activity is evoked when adipocyte differentiation starts,
and it transfers hormonal stimulation to its target genes,
one of which is C/EBPα. When C/EBPα responds to a
PPARγ stimulus, it cooperates with PPARγ to achieve adi-
pocyte differentiation. Although the initial expression of
C/EBPα is induced by the PPARγ signal, it functions to
further strengthen PPARγ activities by stimulating many
specific genes required for adipocyte differentiation [26].
Additionally, SREBP1c is required for optimal adipocyte
differentiation. It regulates the transcription of many
genes related to lipid, fatty acid, and glucose metabolism
[27]. Interestingly, SREBP1c participates in the production
of an endogenous PPARγ ligand that reinforces PPARγ ac-
tivity, which means that PPARγ might be a target gene of
SREBP1c [28]. Thus, PPARγ, C/EBPα, and SREBP1c are
believed to be crucial to, and perform a leading role in,
the progression of adipocyte differentiation. In this study,
we examined the effect of HOX-7 on the expression of
various adipogenesis-related genes and found that HOX-7
inhibited the expression of PPARγ, C/EBPα, and SREBP1c
in epididymal adipose tissues. These results suggest that
HOX-7 exerts anti-obesity effects through the regulation
of adipogenic transcription factors.
The transcription factors aP2 and LPL are downstream
targets of PPARγ and C/EBPα [29]. Therefore, the gene
expression of aP2 and LPL indicates the transcriptional
activities of PPARγ and C/EBPα. We found that HOX-7
suppressed the gene expression of aP2 and LPL, thus
further confirming the inhibitory effect of HOX-7 on the
expression of PPARγ and C/EBPα. LXR is primarily con-
sidered a regulator of cholesterol and fatty acid metabol-
ism in liver tissue and macrophages [30]. LXR similarly
stimulates adipocyte differentiation through the induction
of PPARγ expression [31]. LXR forms a positive relation-
ship with PPARγ and mediates adipogenesis by affect-
ing adipogenic transcriptional factors. In this study,
HOX-7 also attenuated the expression of LXR at the
mRNA level.
Conclusions
In summary, HOX-7 significantly suppressed body and
visceral fat weight in an HFD-induced obese mouse
model. HOX-7 inhibited the expression of adipogenesis-
related genes, such as PPARγ, C/EBPα, and SREBP1c.Our findings suggest that HOX-7 could represent a novel
natural anti-obesity herbal medicine.
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